PubAg

Main content area

Epigenetic potential of resveratrol and analogs in preclinical models of prostate cancer

Author:
Kumar, Avinash, Dhar, Swati, Rimando, Agnes M., Lage, Janice M., Lewin, Jack R., Zhang, Xu, Levenson, Anait S.
Source:
Annals of the New York Academy of Sciences 2015 v.1348 no.1 pp. 1-9
ISSN:
0077-8923
Subject:
antineoplastic activity, bioavailability, biomarkers, chemoprevention, chromatin, epigenetics, lifestyle, microRNA, models, pleiotropy, polyphenols, prostatic neoplasms, resveratrol, tissue culture, New York
Abstract:
Prostate cancer is affected by lifestyle, particularly diet. Dietary polyphenols such as resveratrol possess anticancer properties and, therefore, chemopreventive and therapeutic potentials. Resveratrol has pleiotropic effect exerting its biological activity through multiple pathways and targets associated with cancer. Numerous studies have demonstrated the anticancer effects of resveratrol and to a less extent its analogs, commonly in tissue cultures while in vivo observations are limited. In this review, we provide a concise summary of our results on epigenetic mechanisms of resveratrol and analogs mediated through regulation of chromatin modifier metastasis-associated protein (MTA1) and microRNAs, and highlight the anticancer effects of these compounds in preclinical models of prostate cancer. It is our hope that identified stilbene responsive mechanism-based biomarkers such as MTA1 and oncomiRs may become indicative of treatment efficacy in prostate cancer. Resveratrol analogs with better bioavailability, therefore conferring superior pharmacological potencies and greater anticancer effects, may be stronger candidates for clinical development.
Agid:
62242
Handle:
10113/62242